Skip to content
MamaGLP — home

Compare · a gentle first step

Compare GLP-1 providers, head to head.

Every provider we review, set side by side on the Mama-Match Score — our first-timer rubric that weights a gentle start, honest pricing, real clinician support, nationwide access, ongoing help and fair cancellation. Pick a head-to-head, or find alternatives to a provider you are considering.

Featured provider

CoreAge Rx

Mama-Match

Compounded semaglutide and tirzepatide with advertised flat prices; clarify the offer and renewal rules before paying.

Grade C · Mama-Match Score 73/100. See how it compares with any provider below.

See how every provider ranks against CoreAge Rx on our full ranking →

Compare any two

Pick any two providers. Every pairing works, not just the ones we have written up.

Higher score

Pallas Health

86/100

Semaglutide
$199 every 4 weeks after $139 initial
Tirzepatide
$299 every 4 weeks after $179 initial
Coverage
All 50 states and D.C. network; appointment requirements vary
Brand pens
Yes
Oral option
Yes
Visit Pallas Health Read the Pallas Health review

Rank #2

Trimi Health

85/100

Semaglutide
$175/mo
Tirzepatide
$235/mo
Coverage
Advertises all 50 states; confirm your location
Brand pens
Compounded only
Oral option
No
Read the Trimi Health review

Pallas Health scores higher on the Mama-Match Score. That is the whole verdict: we do not weigh anything into this comparison that is not in the score.

Written up in full

The head-to-heads we've published

These are the pairings with a full write-up behind them, so they lean toward providers we partner with. For any other two, use the comparator above — it covers every pair on the same rubric.

Not quite what you were looking for?

Find alternatives to any provider

Jump to a letter, or scroll — every provider we review is here.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Mama-Match Score, which is our editorial judgment under the methodology. Not medical advice; see our disclosure.